KRC-108

06/12/2015 - "This study suggests that KRC-108 has potential for development as an anti-tumor agent, although further studies are needed. "
07/01/2022 - "These results indicate that KRC-108 may be a promising therapeutic agent for Trk fusion-positive cancers."
06/12/2015 - "The reported in vivo anti-tumor effects of KRC-108 might partly be due to anti-Aurora A effects. "
04/01/2012 - "The GI(50) values (i.e., 50% inhibition of cell growth) for KRC-108 ranged from 0.01 to 4.22 μM for these cancer cell lines. "
04/01/2012 - "The anti-proliferative activity of KRC-108 was measured by performing a cytotoxicity assay on a panel of cancer cell lines. "

06/12/2015 - "KRC-108 induces cell-cycle arrest and apoptosis in colorectal cancer cell line by Aurora A inhibition. "
06/12/2015 - "KRC-108 exhibited cytotoxicity against human colorectal cancer cell line HT-29. "
06/12/2015 - "Effects of KRC-108 on the Aurora A activity and growth of colorectal cancer cells."
04/01/2012 - "KRC-108 was also effective for the inhibition of tumor growth in human HT29 colorectal cancer and NCI-H441 lung cancer xenograft models in athymic BALB/c nu/nu mice. "

04/01/2012 - "KRC-108 was also effective for the inhibition of tumor growth in human HT29 colorectal cancer and NCI-H441 lung cancer xenograft models in athymic BALB/c nu/nu mice. "

02/01/2016 - "In the present study, the changes accompanying resistance to KRC-108 were investigated in the gastric cancer cell line MKN-45 and its KRC-108-resistant clones by western blot and immunofluorescence analyses. "
02/01/2016 - "Resistance to the c-Met inhibitor KRC-108 induces the epithelial transition of gastric cancer cells."

07/01/2022 - "KRC-108 inhibited TrkA activity in an in vitro kinase assay, and suppressed the growth of KM12C colon cancer cells harboring an NTRK1 gene fusion. "